ECS16 THE CORNEAT ESHUNT, CORNEAT VISION’S REVOLUTIONARY GLAUCOMA DRAINAGE DEVICE: EXTENDING MINIMALLY INVASIVE SURGERY TO SEVERE AND REFRACTORY PATIENTS G. Litvin1,* 1CorNeat Vision, Raanana, Israel CorNeat Vision has developed a number of medical devices, first and foremost the CorNeat eShunt, a revolutionary glaucoma drainage device, that provides, for the first time, a long-lasting, minimally invasive […]
ECS06 SUBSTITUTION REGENERATIVE THERAPIES FOR LIMBAL, ENDOTHELIAL, AND RETINAL DYSFUNCTION M. V. Tsurkan1,* 1TissueGUARD GmbH, Dresden, Germany TissueGUARD GmbH is a privately-funded biotechnology company dedicated to developing and producing advanced hydrogel materials as medical devices. Our mission is to create innovative biotechnology solutions for tissue and organoid engineering as regenerative therapeutics. At TissueGUARD, we have […]
Cataract surgery is the most commonly performed operation worldwide (Lindstrom, 2015). In the EU alone \>4.3M operations are performed annually(65% of patients are 65+). The leading post-surgical complication is inflammation, causing pain and, if left untreated, visual loss. Extremely high post-cataract surgery inflammation risk mandates a post-operative care routine with all patients requiring corticosteroid eye […]
Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant to treat glaucoma. Avisi is developing a portfolio of medical devices for eye care. Commercializing a patented metamaterial platform technology First product is VisiPlate, a minimally […]
Twenty/Twenty Therapeutics is a joint Venture of Verily Life Sciences, an Alphabet Company, and Santen Pharmaceuticals uniquely combining their expertise in technology and pharmaceuticals to develop connected ophthalmic therapeutics and personalized ocular digital health interventions. Supported by more than 400 US and International patents, our groundbreaking devices and therapies will transform the way we approach […]
ECS13 VIALASE DESIGNING AN IMAGE GUIDED FEMTOSECOND LASER FOR GLAUCOMA TREATMENT S. O’neil1,* 1ViaLase, Aliso Viejo, United States ViaLase, Inc. is a globally-minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment […]
ECS14 MIMS: STENT-LESS, SIMPLE AND FAST GLAUCOMA SURGERY Nir Israeli1,* 1Sanoculis Ltd., Kiryat Ono, Israel Sanoculis is an Israel-based company which develops and markets the MIMS® (Minimally Invasive Micro Sclerostomy) device and surgery for the treatment of the Glaucoma. MIMS® is simple, fast, and minimally invasive requiring no stitches, eye-patch, implant or stent. It is […]
m-lab GmbH is a spin-off from the University of Mainz, Germany. We are developing and commercializing innovative point-of-care n(POC) devices and personalized treatment approaches in Ophthalmology. The initial product, a Glaucoma diagnostic platform, will provide early detection of Glaucoma, the most prevalent cause of blindness in the world today, by means of an affordable, easy-to- […]
CILIATECH develops the first implant in the industry to reduce IOP without penetrating the anterior chamber nor creating subconjunctival filtration. CILIATECH’S implant (invented by Dr SOURDILLE) is a Cilioscleral Interpositioning Device (CID) made of hydrophilic hydrogel used in IOLs. This platelike device (6*4*0.4 mm) is designed to separate the sclera and the ciliary muscle that […]
Founded in 2016, NovaSight has experienced rapid growth by delivering end-to-end eye-tracking-based vision care solutions. The company focuses on three major verticals: vision treatment, vision diagnostics and prevention and monitoring of visual health conditions. The CureSight™ is an FDA cleared and CE marked eye tracking-based system for treatment of lazy eye designed to replace the traditional […]
